GCCC 2578 Randomized Photon vs Proton RT for Newly Diagnosed Gynecologic Primaries (NCT07415681) | Clinical Trial Compass
Not Yet RecruitingPhase 2
GCCC 2578 Randomized Photon vs Proton RT for Newly Diagnosed Gynecologic Primaries
United States116 participantsStarted 2026-03
Plain-language summary
The purpose of study is to compare the side effects of two different forms of radiation for endometrial and cervical cancer. If you decide to enroll in this study, you will be randomized to one of two treatment groups. This study will compare two standard of care treatments: "Conventional" pHoton radiation versus pRoton radiation.
Who can participate
Age range18 Years
SexFEMALE
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion criteria
✓. a. Newly diagnosed endometrial cancer after TAH/BSO and nodal sampling, sentinel LN biopsy or pelvic nodal dissection planning to receive sequential chemotherapy and radiation or concurrent chemoradiotherapy or b. cervical cancer planning to receive definitive chemoradiation with HDR brachytherapy boost
✓. Histologic confirmation of malignancy (primary only)
✓. ≥ 18 years of age
✓. ECOG performance status ≤ 2
✓. Patient must have the ability to understand and the willingness to sign a written informed consent document or when appropriate, have an acceptable surrogate capable of giving consent on the subject's behalf.
✓. Insurance approval for IMPT
Exclusion criteria
✕. Metastatic disease beyond para-aortic lymph nodal region
✕. Residual tumor after surgery exceeding 2 cm in maximum dimension in patients with endometrial cancer.
✕. FIGO 2014 stage III-IVA cervix cancer planning to receive concurrent pembrolizumab.
✕. Cervical cancer with inability to receive concurrent chemotherapy.
✕. Any prior pelvic radiation.
✕. Treatment with other investigational agents.
What they're measuring
1
Number of participants with treatment-related Acute Gastrointestinal Toxicity as assessed by CTCAE v 5.0
Timeframe: 2-years following completion of treatment